Single‐Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea
暂无分享,去创建一个
Michael R. Wierzbicki | J. Marrazzo | E. Hook | A. Seña | K. Lawrence | B. Batteiger | S. Taylor | Jill Long | Hannah Kwak | S. Johnson | John D. Mueller
[1] A. Katz. Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017 , 2018, Emerging infectious diseases.
[2] K. Holmes,et al. Increases in Neisseria gonorrhoeae With Reduced Susceptibility to Azithromycin Among Men Who Have Sex With Men in Seattle, King County, Washington, 2012–2016 , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] O. Lund,et al. Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017 , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[4] J. Papp,et al. Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016 , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] K. Holmes,et al. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. , 2016, Morbidity and mortality weekly report. Surveillance summaries.
[6] M. Golden,et al. A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] K. Workowski,et al. Sexually transmitted diseases treatment guidelines, 2015. , 2015, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[8] J. Papp,et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] M. Unemo,et al. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults , 2013, International journal of STD & AIDS.
[10] I. Martin,et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. , 2013, JAMA.
[11] M. Unemo,et al. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. , 2012, Future microbiology.
[12] K. Holmes,et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). , 2012, Sexually transmitted diseases.
[13] J. Papp,et al. Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. , 2012, MMWR. Morbidity and mortality weekly report.
[14] Josefina Ayats,et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. , 2012, The Journal of antimicrobial chemotherapy.
[15] J. Wasserheit,et al. The emerging threat of untreatable gonococcal infection. , 2012, The New England journal of medicine.
[16] M. Unemo,et al. High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure , 2011, Antimicrobial Agents and Chemotherapy.
[17] C Bignell,et al. UK national guideline for the management of gonorrhoea in adults, 2011 , 2011, International journal of STD & AIDS.
[18] M. Unemo,et al. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future , 2011, Annals of the New York Academy of Sciences.
[19] M. Unemo,et al. Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone , 2011, Antimicrobial Agents and Chemotherapy.
[20] K. Sankar,et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[21] R. Kirkcaldy,et al. Gonococcal Resistance: Are Cephalosporins Next? , 2011, Current infectious disease reports.
[22] Makoto Ohnishi,et al. Ceftriaxone-Resistant Neisseria gonorrhoeae, Japan , 2011, Emerging infectious diseases.
[23] M. Unemo,et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[24] L. Ng,et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] A. Winston,et al. Pharyngeal gonorrhoea – is dual therapy the way forward? , 2007, International journal of STD & AIDS.
[26] K. Holmes,et al. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. , 2007, MMWR. Morbidity and mortality weekly report.
[27] H. Young,et al. The outcome of oropharyngeal gonorrhoea treatment with different regimens , 2005, International journal of STD & AIDS.
[28] Catherine A McLean,et al. The Emergence of Neisseria gonorrhoeae With Decreased Susceptibility to Azithromycin in Kansas City, Missouri, 1999 to 2000 , 2004, Sexually transmitted diseases.
[29] W. Levine,et al. Drugs of choice for the treatment of uncomplicated gonococcal infections. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] D. Schlossberg,et al. Multicenter Trial of Single‐Dose Azithromycin vs. Ceftriaxone in the Treatment of Uncomplicated Gonorrhea , 1994, Sexually transmitted diseases.
[31] J. Fleiss,et al. Statistical methods for rates and proportions , 1973 .
[32] Mary Jane Ferraro,et al. Performance standards for antimicrobial susceptibility testing : twelfth informational supplement , 2002 .
[33] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .